SENSEX NIFTY
Oct 03, 2011, 03.56 PM IST | Source: Moneycontrol.com

Vivimed Labs acquires privately held Klar Sehen

Vivimed Labs has acquired entire equity stake in Kolkata-based privately held pharma company Klar Sehen to boost its domestic presence specialty medicine areas.

Vivimed Labs acquires privately held Klar Sehen
Moneycontrol Bureau

Vivimed Labs has acquired entire equity stake in Kolkata-based privately held pharma company Klar Sehen to boost its domestic presence in specialty medicine areas.

The financial terms of the deal were not disclosed.

The 30-year-old company operates in a niche ophthalmic segment and owns about 50 trademarks and brands like Renicol, Dexacort, Lysicon-V,  in eye care, Vivimed said Monday.

Klar Sehen has strong marketing presence in North East, Bihar and Andhra Pradesh, it said. It has manufacturing facilities at Kolkata and Hyderabad and also has arrangements to manufacture some of its products in Uttarakhand, and operates with over 150 medical sales professionals, Vivimed said.

Earlier last month Vivimed had completed the acquisition of Octtantis Nobel, a Hyderabad-based pharmaceutical marketing company.

Vivimed Labs shares were trading up 1.2% at Rs 247.50 on NSE on Monday.

Vivimed Labs stock price

On November 21, 2014, Vivimed Labs closed at Rs 383.90, up Rs 8.35, or 2.22 percent. The 52-week high of the share was Rs 424.40 and the 52-week low was Rs 159.00.


The company's trailing 12-month (TTM) EPS was at Rs 12.72 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 30.18. The latest book value of the company is Rs 229.84 per share. At current value, the price-to-book value of the company is 1.67.

Set email alert for

ADS BY GOOGLE

video of the day

Be careful while betting on midcaps; like Kotak: Dimensions

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.